Details of Disease

General Information of Disease (ID: DISPWU75)

Disease Name Influenza virus infection
Disease Class 1E30-1E32: Influenza
Disease Hierarchy
DIS01GPL: Grass pollen hypersensitivity
DISPWU75: Influenza virus infection
ICD Code
ICD-11
ICD-11: 1E30-1E32

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 50 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Agriflu DM1K9SM Approved NA [1]
Arbidol DMOQK8Z Approved Small molecular drug [2]
Arepanrix DMVMY7K Approved Vaccine [1]
Baloxavir marboxil DM1UV7F Approved NA [3]
Celtura DMTIUFA Approved Vaccine [1]
Celvapan DM9KVO4 Approved NA [1]
CSL-425 DML5W87 Approved NA [1]
FluBlok DMMSMZ9 Approved NA [1]
Flucelvax Quadrivalent DM16PSQ Approved Vaccine [4]
FluLaval DMN7HOW Approved NA [1]
Fluvax DMICGJ0 Approved NA [1]
Fluvirin DM1H5ZW Approved Vaccine [1]
Fluzone QIV DML6IDH Approved NA [5]
Focetria A(H1N1) DM2PSBE Approved Vaccine [1]
GC-501 DMKJIVC Approved NA [1]
GSK2592984A DM8QB0T Approved Vaccine [1]
H1N1 HA flu vaccine DMKU8EJ Approved NA [1]
H1N1 influenza vaccine DM10666 Approved NA [1]
H1N1 influenza vaccine DMDJNP7 Approved NA [1]
H1N1 influenza vaccine DMPEBKZ Approved NA [1]
H1N1 influenza vaccine DMZHLS0 Approved NA [1]
H1N1 pandemic influenza A vaccine DMFUAXT Approved Vaccine [1]
H1N1 pandemic influenza vaccine DMX2O9B Approved NA [1]
H5N1 avian influenza vaccine DMV7XPS Approved NA [1]
H5N1 influenza vaccine DMO6AZC Approved NA [6]
Inflexal V DMKQTJB Approved NA [1]
Influenza vaccine DMZVCUU Approved NA [1]
Influenza virus vaccine DMKIRDY Approved NA [1]
Ingavirin DMR2K3C Approved NA [1]
Intanza DME4ZEE Approved NA [1]
Live attenuated H1N1 pandemic influenza vaccine DMF36ZP Approved NA [1]
Live attenuated influenza vaccine DMX9PIA Approved Vaccine [1]
NasoVac DMOXFGW Approved NA [1]
NKM DMLOTVB Approved NA [1]
Optaflu DMMEZNU Approved NA [1]
Oseltamivir DMGO72P Approved Small molecular drug [7]
Pandemrix DM0KI8E Approved Vaccine [8]
Peramivir DMNXY5K Approved Small molecular drug [9]
Preflucel DMH4FMB Approved NA [1]
Rimantadine DM5DWMU Approved Small molecular drug [10]
Split virion H1N1 influenza vaccine DMT0OUF Approved NA [1]
TP-434 DM5A31S Approved Small molecular drug [11]
VaxiFlu-S DMABQBY Approved NA [1]
Yuganning DMJZV6Y Approved NA [1]
Zanamivir DMFMBZ4 Approved Small molecular drug [12]
BLB-750 DMJI6YI Registered NA [13]
Favipiravir DMBZ27L Registered Small molecular drug [1]
H5N1 influenza vaccine DMV44UT Registered NA [14]
PandyFlu DM71NT1 Registered NA [15]
Iota-carrageenan DM8QGTB Phase 4 NA [16]
------------------------------------------------------------------------------------
⏷ Show the Full List of 50 Drug(s)
This Disease is Treated as An Indication in 109 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Afluria Quadrivalent DMXYDCO Phase 3 NA [5]
BK-PIFA DMKRM3P Phase 3 NA [17]
CS-8958 DM4CSDH Phase 3 Small molecular drug [18]
FluNhance DMZS2XF Phase 3 NA [5]
GLYCYRRHIZIN DM8M2N3 Phase 3 Small molecular drug [19]
Grippol Plus DM71GPM Phase 3 Vaccine [20]
Grippol TC DMB34TZ Phase 3 Vaccine [20]
GSK-2282512A DMMKF9V Phase 3 NA [21]
GSK2321138A DMO6U80 Phase 3 NA [22]
H1N1 influenza A inactivated split virion vaccine DMHDY52 Phase 3 NA [23]
H1N1 influenza vaccine DMAXTFO Phase 3 Vaccine [24]
H1N1 influenza vaccine DMS7JZH Phase 3 NA [25]
H5N1 influenza vaccine DM9CMI3 Phase 3 Vaccine [26]
H5N1 influenza vaccine DMCGGJA Phase 3 NA [27]
H5N1 influenza vaccine DME2PYB Phase 3 NA [28]
H5N1 influenza vaccine DMGJNUF Phase 3 NA [29]
Improved influenza vaccine DMUGB8M Phase 3 NA [30]
Influenza A virus H5N1 vaccine DMGNPDR Phase 3 NA [5]
Influenza cell culture vaccine DMLXOXZ Phase 3 NA [31]
Influenza virus vaccine quadrivalent DMGZQWX Phase 3 NA [5]
Influvac TC DMWDYZ2 Phase 3 NA [32]
Lnfluvac TC DMPI3K6 Phase 3 NA [32]
MEDI-8662 DM68O6T Phase 3 NA [33]
MG-1109 DMFJBHK Phase 3 NA [34]
RBT-101 DMDZW8K Phase 3 NA [35]
Seasonal influenza vaccine DMTO9G7 Phase 3 NA [36]
VaxiGrip QIV IM DMD620F Phase 3 NA [5]
Vero cell seasonal influenza vaccine DM7N92T Phase 3 NA [37]
Xilonix DMK34MZ Phase 3 NA [38]
ATL101 DMYAQV2 Phase 2 NA [39]
BAICALEIN DM4C7E6 Phase 2 Small molecular drug [40]
BTL-TML-001 DMY5IX4 Phase 2 NA [41]
CR8020 DMQ47U6 Phase 2 Antibody [42]
CSL-412 DMAO1CT Phase 2 NA [43]
DAS-181 DM0Y8JP Phase 2 NA [44]
DeltaFLU DMN11WR Phase 2 NA [45]
DeltaFLU-LAIV DMCOSLH Phase 2 NA [5]
Fluoropeptide vaccine DMCEUOH Phase 2 Vaccine [46]
GSK-1247446A DMDF6JY Phase 2 NA [47]
GSK-2584786A DM0NQL7 Phase 2 NA [48]
H5N1 influenza vaccine DMCYUPH Phase 2 NA [49]
H5N1 influenza vaccine DMFSMFI Phase 2 NA [50]
H5N1 influenza vaccine DMO4I61 Phase 2 Vaccine [51]
H5N1 vaccine DM4FB6J Phase 2 NA [52]
Immunose FLU DMPKXW3 Phase 2 NA [53]
Influenza A virus H7N9 vaccine DM22AQE Phase 2 NA [5]
Influenza A virus vaccine H5N1 DM0FUFN Phase 2 NA [5]
Influsome-Vac DMBDPTW Phase 2 NA [54]
LIQ-001 DM97C26 Phase 2 NA [55]
Multimeric-001 DMH0SGF Phase 2 NA [56]
Norketotifen DMO5JOA Phase 2 Small molecular drug [57]
NU300 DMO0C5R Phase 2 NA [58]
OrniFlu DMNXQOI Phase 2 NA [59]
PanBlok DMYC0PL Phase 2 NA [60]
proglumide DM4MF9V Phase 2 Small molecular drug [5]
TCN-032 DM9PVNJ Phase 2 Antibody [61]
Trivalent seasonal influenza vaccine DMRVNAU Phase 2 NA [62]
VLP-based influenza vaccine DMJIFFP Phase 2 NA [63]
VR736 DMLEL4A Phase 2 NA [64]
VXA-A1.1 DMMQKEA Phase 2 NA [5]
AVX-502 DM74NU0 Phase 1/2 NA [65]
GHB-16L2 DMK61DJ Phase 1/2 NA [66]
H5N1 influenza vaccine DMNBZGB Phase 1/2 NA [67]
Inactivated H7N7 influenza vaccine DMMJ8WI Phase 1/2 NA [68]
Influenza vaccine patch DMA4FZQ Phase 1/2 NA [69]
Vero-cell H5N1 vaccine DMO40FJ Phase 1/2 NA [70]
A/Anhui/05 DMGJ7A4 Phase 1 Vaccine [71]
ACAM-FLU-A DMZZ2S3 Phase 1 NA [72]
AdCMV-PR8.ha DMB0Z60 Phase 1 NA [73]
AE-443p DM8Q47R Phase 1 NA [74]
AEA-35p DMQRKXP Phase 1 Vaccine [75]
Avian H5N1 influenza vaccine DM80YDI Phase 1 NA [76]
AviFlu DMB7EGS Phase 1 NA [77]
CodaVax-H1N1 DMJ8B2I Phase 1 Vaccine [5]
FGI-101-1A6 DM8U2IE Phase 1 Antibody [78]
FLU-v DMFF4J9 Phase 1 NA [79]
Flufirvitide-3 DMX38G2 Phase 1 NA [80]
FluGEM DMCJPKY Phase 1 NA [81]
GelVac H5N1 influenza virus vaccine DMY4GT3 Phase 1 NA [82]
GSK-2115160A DMXOTP4 Phase 1 NA [83]
GSK-2590066A DMC9RFO Phase 1 NA [84]
H1N1 influenza vaccine DMGYHOS Phase 1 NA [85]
H1N1 influenza vaccine DMYPX3L Phase 1 NA [86]
H1N1 vaccine DMNK80V Phase 1 NA [87]
H2N2 live attenuated influenza vaccine DM6KO62 Phase 1 NA [88]
H2N3 MO 2003/AA DMTIKEF Phase 1 NA [89]
H5N1 pandemic influenza vaccine DMMH13W Phase 1 NA [90]
H6N1 influenza vaccine DME53HS Phase 1 NA [91]
H7N3 avian influenza virus live attenuated vaccine DMZJADL Phase 1 NA [92]
HAC-1 vaccine DMALGTW Phase 1 NA [93]
IC31 seasonal influenza vaccine DMEI7AJ Phase 1 NA [94]
INfluenza A virus H5N8 vaccine DM01IJT Phase 1 NA [5]
Influenza A virus vaccine H1N1 DMKJ3EM Phase 1 NA [5]
Influenza DNA vaccine DM1ND2U Phase 1 NA [95]
Influenza H3N2 vaccine DMAHSPY Phase 1 NA [5]
Influenza subunit vaccines DMEA4S9 Phase 1 NA [96]
Influvac tC cell culture-derived influenza vaccine DM5G5W3 Phase 1 NA [97]
L1Q-001 DMGHDC5 Phase 1 NA [55]
M2e influenza vaccine DMSVABX Phase 1 NA [98]
MER4101 DMNISCH Phase 1 Vaccine [99]
mRNA-1440 DM14Y0B Phase 1 NA [5]
mRNA-1851 DM9Q16B Phase 1 NA [5]
N-8295 DM3PC0J Phase 1 Vaccine [100]
NASPANVAC DMXLLEL Phase 1 NA [101]
ND-1.1 DMVQAEK Phase 1 Vaccine [102]
PANFLUVAC DMYNSTW Phase 1 NA [103]
Radavirsen DMWVYDN Phase 1 Small molecular drug [104]
Vaxfectin plasmid DNA pandemic influenza vaccine DMZV3BN Phase 1 NA [105]
WNV DNA vaccine DMJOYQU Phase 1 NA [106]
------------------------------------------------------------------------------------
⏷ Show the Full List of 109 Drug(s)
This Disease is Treated as An Indication in 8 Discontinued Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
H1N1 influenza vaccine DMWB23S Discontinued in Phase 3 Vaccine [107]
Needle-free influenza vaccine DMK2I8X Discontinued in Phase 2 NA [108]
PF-4522625 DM13ZWH Discontinued in Phase 1 NA [109]
SPD-701 DM4IA2I Discontinued in Phase 1 NA [110]
BCX-140 DMBJERO Terminated Small molecular drug [113]
GS-3435 DMV7JC6 Terminated NA [114]
Nasalflu Berna DMKAHQZ Terminated NA [115]
Recombinant protein subunit vaccine (seasonal influenza) DM174B4 Terminated NA [116]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 Drug(s)
This Disease is Treated as An Indication in 2 Preclinical Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
ALN-FLU01 DM648KQ Preclinical siRNA drug [111]
H5N1 influenza vaccine DMYSTFE Preclinical NA [112]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 2 Investigative Agents
Drug Name Drug ID Highest Status Drug Type REF
Amantidine DMMT5Q4 Investigative Small molecular drug [117]
Triazavirin DMZBU2M Investigative Small molecular drug [119]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 58 Investigative Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Antiviral BMS-1 DM2S6QL Investigative NA [35]
AviFluCide-I DM00BX5 Investigative NA [35]
BDNA-002 DMR27F0 Investigative NA [35]
BPL-004 DM36MK9 Investigative NA [35]
BT-V003 DMO4M4A Investigative NA [35]
BTA-929 DMTOOAI Investigative NA [35]
BVS-212 DMMVO78 Investigative NA [35]
CLVax 1.0 DMHDG0E Investigative NA [35]
CT-120 DMYUCT3 Investigative NA [35]
CTA1-3M2e-DD DMAYNFK Investigative NA [35]
ET-001 DM7GKIE Investigative NA [35]
ETV-005 DMOZQQY Investigative NA [35]
F10 DMI3GIA Investigative NA [35]
FI-6 DM1IQCB Investigative NA [35]
FluBiovax DMVG3EL Investigative NA [35]
FLUINHIBIT DM2UYFW Investigative NA [35]
FluPro DMHFKQL Investigative NA [35]
GM04-001 DMV8SNS Investigative NA [35]
GP-1001 DMZBOOJ Investigative NA [35]
GP-1002 DMFROS5 Investigative NA [35]
H5N1 influenza mab therapy DM2MUNT Investigative Monoclonal antibody [35]
H5N1 pandemic influenza mab DM962NO Investigative Monoclonal antibody [35]
Homspera DMI7258 Investigative NA [118]
IkT-041 DMXPRNC Investigative NA [35]
IkT-051 DMOB0YH Investigative NA [35]
IMM-255 DMOOLY2 Investigative NA [35]
INDUS-82030 DML6MVQ Investigative NA [35]
IPN-120 DMQQ29A Investigative NA [35]
LG-611 DM0GYJZ Investigative NA [35]
M2del11 H1N1 DMM3FJ6 Investigative NA [35]
M2del11 HAavir H5N1 DMLKS3Z Investigative NA [35]
MBX2329 DM88OXD Investigative NA [35]
MD-2009 DMFI31V Investigative NA [35]
MDR-03030 DM1L9X7 Investigative NA [35]
MVAH5 DM0T7AD Investigative NA [35]
Nucleozin DMW866Y Investigative Small molecular drug [35]
Nucleozin analog 3061 (FA-2) DMJ24JA Investigative NA [35]
NVC-612 DMZRSQO Investigative NA [35]
ORMD-1001 DMB4YQS Investigative NA [35]
PAR-401 DMGQB9F Investigative NA [35]
PAV-616 DMI6VU1 Investigative NA [35]
PEV-8 DMTVFAC Investigative NA [35]
Polyflu DM1YZZ7 Investigative NA [35]
SKYFlu DM0PCB2 Investigative NA [35]
SLP-0904 DM74CA9 Investigative NA [35]
SLP-1001 DMVAZQE Investigative NA [35]
STP-702 DMMS14U Investigative NA [35]
Tamiphosphor DMOEVP5 Investigative Small molecular drug [35]
TG-21 DMRXDRW Investigative NA [35]
TR-Flu DMXIH6P Investigative NA [35]
TVX-001 DMH2Y5A Investigative NA [35]
TVX-002 DMBQCVT Investigative NA [35]
TVX-003 DMYAUBA Investigative NA [35]
TVX-004 DMLBCLL Investigative NA [35]
TVX-005 DMIPUKX Investigative NA [35]
Ultragrivak DMPLGUV Investigative NA [35]
VG-FLU DMGWZ9N Investigative NA [35]
Zofroxia DM2EVW6 Investigative NA [35]
------------------------------------------------------------------------------------
⏷ Show the Full List of 58 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 ClinicalTrials.gov (NCT01651663) A Study of Arbidol (Umifenovir) for Treatment and Prophylaxis of Influenza and Common Cold (ARBITR)
3 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Clinical pipeline report, company report or official report of Sinovac Biotech Ltd.
7 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
8 ClinicalTrials.gov (NCT01730378) Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years Old. U.S. National Institutes of Health.
9 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
10 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 076132.
11 ClinicalTrials.gov (NCT01265784) Study to Compare TP-434 and Ertapenem in CA Complicated Intra-abdominal Infections. U.S. National Institutes of Health.
12 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 021036
13 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032796)
14 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020843)
15 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800039976)
16 ClinicalTrials.gov (NCT01944631) Iota-Carrageenan Nasal Spray in Common Cold. U.S. National Institutes of Health.
17 Characterization of a whole, inactivated influenza (H5N1) vaccine. Influenza Other Respir Viruses. 2008 Nov;2(6):261-6.
18 ClinicalTrials.gov (NCT00803595) A Multinational Phase III Study of CS-8958 (MARVEL). U.S. National Institutes of Health.
19 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4688).
20 Clinical pipeline report, company report or official report of Solvay SA.
21 ClinicalTrials.gov (NCT01204671) Safety and Immunogenicity Study of GSK Biologicals' Seasonal Influenza Candidate Vaccine (GSK2321138A). U.S. National Institutes of Health.
22 ClinicalTrials.gov (NCT01439360) An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children. U.S. National Institutes of Health.
23 ClinicalTrials.gov (NCT01201902) A Study to Evaluate the Safety and Immunogenicity of an Inactivated Split-virion Influenza A(H1N1) Vaccine. U.S. National Institutes of Health.
24 Clinical pipeline report, company report or official report of Sanofi Pasteur.
25 Clinical pipeline report, company report or official report of Daiichi Sankyo.
26 Clinical pipeline report, company report or official report of Daiichi Sankyo.
27 Use of licensed H5N1 influenza vaccines in the interpandemic period.
28 Clinical pipeline report, company report or official report of Denka Seiken Co Ltd.
29 Use of licensed H5N1 influenza vaccines in the interpandemic period.
30 ClinicalTrials.gov (NCT00529516) Evaluate Safety & Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults. U.S. National Institutes of Health.
31 ClinicalTrials.gov (NCT00310804) Safety and Immunogenicity of 3 Lots of Cell-derived Subunit Influenza Vaccine as Compared to 1 Lot to Egg-derived Subunit Influenza Vaccine in Healthy Adults (>=18 to<=60). U.S. National Institutes of Health.
32 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031619)
33 ClinicalTrials.gov (NCT00952705) A Study to Evaluate the Immunogenicity of Quadrivalent LAIV (MEDI8662) in Adults 18 to 49 Years of Age. U.S. National Institutes of Health.
34 ClinicalTrials.gov (NCT01987011) Phase III Study to Evaluate the Immunogenicity and Safety of MG1109 in Healthy Adult Volunteers. U.S. National Institutes of Health.
35 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
36 Immunogenicity and safety of Fluzone( ) intradermal and high-dose influenza vaccines in older adults 5 years of age: a randomized, controlled, phase II trial. Vaccine. 2014 May 1;32(21):2507-17.
37 Clinical pipeline report, company report or official report of Baxter.
38 Clinical pipeline report, company report or official report of Xbiotech.
39 Clinical pipeline report, company report or official report of Atlab pharma.
40 ClinicalTrials.gov (NCT03830684) A Randomized, Double-blind, Placebo-controlled, Multicenter and Phase IIa Clinical Trial for the Effectiveness and Safety of Baicalein Tablets in the Treatment of Improve Other Aspects of Healthy Adult With Influenza Fever. U.S. National Institutes of Health.
41 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031551)
42 ClinicalTrials.gov (NCT01992276) Assessment of Efficacy of CR8020 and CR6261, Monoclonal Antibodies, Against Influenza Infection. U.S. National Institutes of Health.
43 ClinicalTrials.gov (NCT00479648) A Phase 2 Study of Immunogenicity, Safety and Tolerability of CSL412 in Elderly Participants. U.S. National Institutes of Health.
44 Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein. PLoS One. 2009 Nov 6;4(11):e7838.
45 ClinicalTrials.gov (NCT01078701) Dose Finding Study of Single Dose GHB11L1 in Healthy Adults. U.S. National Institutes of Health.
46 ClinicalTrials.gov (NCT01703923) An Exploratory Study of FP01 Lozenges in Subjects With Chronic Refractory Cough. U.S. National Institutes of Health.
47 ClinicalTrials.gov (NCT00545025) Revaccination With Influenza Vaccine GSK1247446A. U.S. National Institutes of Health.
48 ClinicalTrials.gov (NCT01195779) Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children. U.S. National Institutes of Health.
49 Clinical pipeline report, company report or official report of Medicago Inc.
50 ClinicalTrials.gov (NCT00561184) Safety and Immunogenicity of a Booster Dose of -H5N1 Influenza Vaccine. U.S. National Institutes of Health.
51 ClinicalTrials.gov (NCT00430521) Safety & Immunogenicity of an Alternative Immunization Schedule of GSK Bio's Pandemic Influenza Vaccine (GSK1119711A). U.S. National Institutes of Health.
52 Avian Influenza Trials. National Institute of Allergy and Infectious Diseases (NIAID) in NIH. January 30, 2007.
53 Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer. 2007 Jul 15;110(2):244-54.
54 Particle-mediated delivery of cytokines for immunotherapy. Immunotherapy. 2012 Apr;4(4):425-41.
55 ClinicalTrials.gov (NCT01224262) A Study Evaluating the Safety and Tolerability of a Seasonal Influenza Vaccine Containing LIQ001. U.S. National Institutes of Health.
56 ClinicalTrials.gov (NCT01146119) Further Investigation of an Intramuscular Influenza Vaccine (Multimeric-001). U.S. National Institutes of Health.
57 ClinicalTrials.gov (NCT04043923) Norketotifen for the Treatment of Uncomplicated Influenza-like Illness. U.S. National Institutes of Health.
58 ClinicalTrials.gov (NCT01732198) A Phase 2, Multicenter, Open-label Study to Assess the Immunogenicity of an Investigational Hib Vaccine (NU300)in Toddlers. U.S. National Institutes of Health.
59 ClinicalTrials.gov (NCT02153671) Immunogenicity of H5N1 Vaccine Following H5N2. U.S. National Institutes of Health.
60 ClinicalTrials.gov (NCT01612000) Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults. U.S. National Institutes of Health.
61 ClinicalTrials.gov (NCT01719874) Influenza Virus Challenge Study to Test Monoclonal Antibody TCN-032 as a Treatment for Influenza. U.S. National Institutes of Health.
62 Clinical pipeline report, company report or official report of Juvaris BioTherapeutics Inc.
63 Clinical pipeline report, company report or official report of Novavax.
64 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800038131)
65 ClinicalTrials.gov (NCT00706732) A Safety and Immunogenicity Trial in Adults 65 Years of Age or Over to Prevent Influenza. U.S. National Institutes of Health.
66 ClinicalTrials.gov (NCT01369862) Study of Single Dose GHB16L2 Trivalent Influenza Vaccine in Healthy Adults. U.S. National Institutes of Health.
67 Clinical pipeline report, company report or official report of Novavax.
68 ClinicalTrials.gov (NCT00546585) Safety, Reactogenicity, and Immunogenicity of Inactivated Influenza A/H7/N7 Vaccine in Healthy Adults. U.S. National Institutes of Health.
69 Transcutaneous delivery and thermostability of a dry trivalent inactivated influenza vaccine patch. Influenza Other Respir Viruses. 2008 Mar;2(2):53-60.
70 Safety and immunogenicity of a vero cell culture-derived whole-virus H5N1 influenza vaccine in chronically ill and immunocompromised patients. Clin Vaccine Immunol. 2014 Jun;21(6):867-76.
71 ClinicalTrials.gov (NCT00912496) Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59. U.S. National Institutes of Health.
72 ClinicalTrials.gov (NCT00819013) Safety Study of Recombinant M2e Influenza-A Vaccine in Healthy Adults. U.S. National Institutes of Health.
73 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800042086)
74 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026774)
75 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035645)
76 ClinicalTrials.gov (NCT00694213) Pandemic Influenza Plasmid DNA Vaccines (Needle-Free). U.S. National Institutes of Health.
77 ClinicalTrials.gov (NCT01719783) Reactogenicity, Safety, and Immunogenicity of a Live Monovalent H5N2 Influenza Vaccine. U.S. National Institutes of Health.
78 ClinicalTrials.gov (NCT01299142) Safety and Pharmacokinetics Study of Human Monoclonal Antibody (FGI-101-1A6). U.S. National Institutes of Health.
79 ClinicalTrials.gov (NCT01181336) Phase 1b Influenza Vaccine Study in Healthy Subjects. U.S. National Institutes of Health.
80 ClinicalTrials.gov (NCT01313962) Safety Study of Flufirvitide-3 Nasal Spray in Healthy Subjects. U.S. National Institutes of Health.
81 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800039040)
82 Clinical pipeline report, company report or official report of Nanotherapeutics.
83 ClinicalTrials.gov (NCT00714285) Immunogenicity and Safety Study of a GSK Influenza Vaccine Candidate in Adults.. U.S. National Institutes of Health.
84 ClinicalTrials.gov (NCT01236040) Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old. U.S. National Institutes of Health.
85 Clinical pipeline report, company report or official report of Medicago Inc.
86 New Vaccine Technologies. National Institute of Allergy and Infectious Diseases (NIAID) in NIH. January 14, 2011.
87 Clinical pipeline report, company report or official report of Vical.
88 ClinicalTrials.gov (NCT00722774) Safety and Immune Response to Recombinant Live-Attenuated Influenza H2N2 Virus Vaccine. U.S. National Institutes of Health.
89 ClinicalTrials.gov (NCT01175122) Evaluation of the Safety and Immunogenicity of a Live Attenuated Virus Vaccine for the Prevention of H2N3 Influenza. U.S. National Institutes of Health.
90 Clinical pipeline report, company report or official report of Sanofi Pasteur.
91 ClinicalTrials.gov (NCT00734175) Safety of and Immune Response to Recombinant Live-Attenuated Influenza H6N1 Virus Vaccine Vaccine. U.S. National Institutes of Health.
92 A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults. Vaccine. 2009 Jun 8;27(28):3744-53.
93 Safety and immunogenicity of a plant-produced recombinant monomer hemagglutinin-based influenza vaccine derived from influenza A (H1N1)pdm09 virus: a Phase 1 dose-escalation study in healthy adults. Vaccine. 2014 Apr 17;32(19):2251-9.
94 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027863)
95 ClinicalTrials.gov (NCT00349037) Study of the Ability of a Flu Vaccine to Prevent Flu Infection. U.S. National Institutes of Health.
96 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021663)
97 Clinical pipeline report, company report or official report of Abbott Laboratories.
98 Clinical pipeline report, company report or official report of VaxInnate Corporation.
99 ClinicalTrials.gov (NCT02500680) The Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101).
100 Clinical pipeline report, company report or official report of Dynavax Technologies Corp.
101 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032245)
102 ClinicalTrials.gov (NCT01698060) Immunogenicity of ND1.1 by Delivery Directly to the Ileum. U.S. National Institutes of Health.
103 ClinicalTrials.gov (NCT00868218) Study of a Parenterally Administered H5N1 Influenza Vaccine in Healthy Adults. U.S. National Institutes of Health.
104 ClinicalTrials.gov (NCT01747148) Testing the AVI-7100 Flu Drug in Healthy Volunteers. U.S. National Institutes of Health.
105 Clinical pipeline report, company report or official report of Vical.
106 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019779)
107 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800039884)
108 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024213)
109 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021770)
110 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009337)
111 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022658)
112 Clinical pipeline report, company report or official report of BioDiem Ltd.
113 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006335)
114 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005196)
115 Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine. Vaccine. 2009 Jul 16;27(33):4381-7.
116 The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease. Vaccine. 2011 Sep 23;29(42):7267-75.
117 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 209171.
118 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 360).
119 A New Antiviral Drug Triazavirin: Results of Phase II Clinical Trial. Vopr Virusol. Nov-Dec 2012;57(6):9-12.